Investigational drug · Phase 2
AK119
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer, Solid Tumor, Adult.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "AK119"
First trial start
2023
Apr 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK119", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
- Solid Tumor, Adult
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK119" as an intervention, largest first.
- A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal CancerActive, not recruiting
AkesoIndustry
NCT05846867 · 170 participants (planned) · Start May 8, 2023 · Primary completion May 8, 2026
Drug: AK119; AK112 and 4 more · For: Colorectal Cancer
Sites: Harbin, China
AkesoIndustry
NCT05689853 · 87 participants (planned) · Start Apr 14, 2023 · Primary completion Dec 2026
Drug: AK119; AK112 · For: Solid Tumor, Adult
Sites: Beijing, China
AkesoIndustry
NCT05636267 · 59 participants · Start Feb 10, 2023 · Primary completion Feb 24, 2025
Drug: AK119; AK112 and 2 more · For: NSCLC
Sites: Guangzhou, China
AkesoIndustry
NCT05559541 · 33 participants · Start Dec 15, 2022 · Primary completion May 31, 2024
Drug: AK119; AK104 · For: Solid Tumor, Adult
Sites: Tianjin, China
Akesobio Australia Pty LtdIndustry
NCT04516564 · 29 participants · Start Sep 28, 2020 · Primary completion May 4, 2021
Drug: AK119; Placebo · For: Coronavirus Disease 2019 (COVID-19)
Sites: Christchurch, New Zealand
- A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid TumorsCompleted
AkesoIndustry
NCT04572152 · 23 participants · Start Dec 7, 2020 · Primary completion May 2, 2023
Drug: AK119; AK104 · For: Advanced or Metastatic Solid Tumors
Sites: Blacktown, Australia; South Brisbane, Australia; Adelaide, Australia · 5 sites in all
AkesoIndustry
NCT05173792 · 16 participants · Start Dec 22, 2021 · Primary completion May 22, 2023
Drug: AK119 · For: Solid Tumor
Sites: Shanghai, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- Coordinated V gamma and V delta gene segment rearrangements in human T cell receptor gamma/delta+ lymphocytes.
Sturm E, Braakman E, Bontrop RE, et al. · Eur J Immunol 1989
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.